Publications by authors named "Chasapi V"
Article Synopsis
- * A study in Greece involved 184 adults, revealing that many suffer from additional issues like obesity and allergic comorbidities, with the majority receiving specific treatment for their condition.
- * Key findings included high rates of pain, severe itching, and sleep disturbances, with patients reporting substantial reductions in work productivity and overall well-being.
Article Synopsis
- Bimekizumab is a monoclonal antibody that targets interleukin-17A and interleukin-17F, proving to be very effective for treating chronic plaque psoriasis with a quick impact based on Randomized Controlled Trials (RCTs).
- A study in Athens involved 61 patients with moderate-to-severe psoriasis, revealing that a significant percentage achieved marked improvement (PASI75: 65.7%, PASI90: 45.7%, PASI100: 32.4%) after just 4 weeks and even higher rates after 16 weeks.
- The safety profile showed a few mild-to-moderate adverse events, including oral candidiasis, aligning with
Article Synopsis
- Dermatitis artefacta, also known as factitious dermatitis, manifests differently across the body and is often linked to psychological distress, such as borderline personality disorder and the risk of self-harm for attention.
- A case study involves a 17-year-old girl with anxiety symptoms preparing for university who developed an ulcer on her ankle due to factitious disorder, revealing a need for emotional support rather than physical illness.
- Treatment focuses on psychotherapy for the mental health aspect, while the ulcer necessitates dermatosurgical care to address the physical condition.
Article Synopsis
- - The BrIDGE study examined the real-world effectiveness of brodalumab in treating moderate-to-severe plaque psoriasis in Greece, focusing on the percentage of patients achieving complete clearance (PASI100) over 24 weeks and beyond.
- - Results showed that 42% of patients reached PASI100 at Week 24, with this number increasing to 65% by Week 104, while significant improvements were noted in other assessment scores (PASI75, PASI90, and sPGA).
- - Additionally, patients reported improved quality of life, with average scores on the Dermatology Life Quality Index (DLQI) decreasing significantly over the study period, indicating better overall well-being as a result of brodalumab treatment
Cutaneous melanoma metastases: Clinical and dermoscopic findings.
J Eur Acad Dermatol Venereol
May 2023
Article Synopsis
- The study focused on the clinical and dermoscopic characteristics of cutaneous melanoma metastases (CMM) in 42 melanoma patients, noting that accurate diagnosis remains difficult due to variability in these features.
- Results showed that both male and female patients exhibited different dermoscopic patterns of CMM, with the homogenous and amelanotic types being the most prevalent, and specific patterns associated with the depth of the primary melanoma.
- The findings suggest that deeper melanomas are more likely to show vascular structures in their metastases, and in some cases, CMM may be the first sign of underlying melanoma.
Article Synopsis
- Brodalumab has shown significant clinical effectiveness and a good safety record in controlled trials, but limited real-world data exists; the BrIDGE study in Greece aims to fill this gap by observing treatment outcomes in moderate-to-severe plaque psoriasis patients over 104 weeks.* -
- Early results from the study, covering 12-16 weeks post-treatment initiation, indicate that 72.8% of patients achieved a "clear/almost clear" skin rating, with varying percentages reaching significant reductions in psoriasis severity scores (PASI75, PASI90, PASI100).* -
- Improvements in symptoms and quality of life were noted alongside a high treatment adherence rate of 90%, and while nine adverse events were recorded, the
Article Synopsis
- Real-world analysis evaluated the long-term benefits of brodalumab for treating moderate-to-severe psoriasis in 180 Greek patients over 24 months.
- The study showed significant improvements in psoriasis severity (measured by PASI scores) and quality of life (measured by DLQI scores) from baseline, with high proportions of patients achieving major reductions in PASI scores as early as 1 month into treatment.
- Overall, the findings support brodalumab's effectiveness in standard clinical practice, highlighting its rapid and sustained positive impact on patients' conditions.
Background: Real-world data in patients with moderate psoriasis treated with apremilast is limited.
Objectives: To evaluate the effectiveness and safety of apremilast in bio-naïve patients with moderate psoriasis in real-world clinical settings.
Methods: This was a 52-week multicenter, observational, prospective study of adult outpatients with moderate psoriasis {[10% < body surface area < 20% or 10 < psoriasis area severity index (PASI) < 20] and 10 < dermatology quality of life index (DLQI) < 20} initiated on apremilast ≤7 days before enrollment.
Article Synopsis
- - The CELSUS study in Greece evaluated the effectiveness of Calcipotriol/Betamethasone (Cal/BD) aerosol foam for psoriasis treatment and found it led to significant patient satisfaction and treatment success across various disease severities.
- - Out of 400 patients, those naïve to treatment had better success rates (72.6% for mild, 56.5% for moderate, and 66.7% for severe) compared to treatment-experienced patients (60.7%, 42.2%, and 25% respectively) after 4 weeks.
- - Overall, both treatment-naïve and treatment-experienced patients showed notable reductions in psoriasis symptoms, with the most significant improvements seen
Article Synopsis
- - Harlequin syndrome is a rare autonomic nervous system disorder that results in reduced facial flushing and sweating on one side, triggered by factors like exercise or stress.
- - The condition is linked to an issue in the cervical sympathetic nerves, specifically on the side that does not flush.
- - The text includes a case study of an 8-year-old with this syndrome and discusses other skin-related conditions that also use the term "harlequin."
Background: Frontal fibrosing alopecia (FFA) has become one of the most common causes of cicatricial alopecia worldwide. However, there is a lack of clear aetiology and robust clinical trial evidence for the efficacy and safety of agents currently used for treatment.
Objectives: To enable data to be collected worldwide on FFA using common criteria and assessment methods.
Background: Apremilast is an oral phosphodiesterase-4 inhibitor indicated for patients with moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis.
Objectives: To examine the effectiveness of apremilast on Dermatology Life Quality Index (DLQI), Psoriasis Area and Severity Index (PASI) and nail, scalp and palmoplantar involvement, when administered prior to biologics.
Methods: This 52-week real-world study included biologic-naive adults with moderate psoriasis (psoriasis-involved body surface area 10% to <20%, or PASI 10 to <20 and DLQI 10 to <20).
Article Synopsis
- - Recent studies suggest a potential link between low serum 25-hydroxyvitamin D levels and a higher incidence of cutaneous malignant melanoma (CMM), indicating worse outcomes for patients with such deficiencies.
- - The research analyzed 99 melanoma patients and 97 healthy controls, measuring their serum vitamin D levels and comparing various risk factors and characteristics related to CMM.
- - Although melanoma patients had lower vitamin D levels than healthy controls, the difference did not achieve statistical significance, and no significant associations with cancer severity or characteristics were found.
Article Synopsis
- Frontal fibrosing alopecia (FFA) is a type of hair loss that has been increasing in prevalence, and this study looks at how social status impacts the disease's prognosis in female patients.
- The research involved 100 women in Greece, averaging 61 years old, with most defined as having at least intermediate education; the disease duration varied from less than a year to 20 years.
- Results showed that women with lower education levels experienced more severe symptoms, suggesting that higher education and social status lead to earlier diagnosis and better treatment outcomes.